Cover Image
Market Research Report
Product code 
1091863

United States Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2028

Published: | Inkwood Research | 150 Pages | Delivery time: 2-3 business days

Price

Back to Top
United States Alzheimer's Disease Therapeutics & Diagnostics Market Forecast 2022-2028
Published: June 21, 2022
Inkwood Research
Content info: 150 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

KEY FINDINGS

The United States Alzheimer's disease therapeutics & diagnostics market is estimated to progress with a 6.62% CAGR during the forecasting years 2022-2028. The market growth is driven by regular cognitive assessments of senior citizens and the easy availability of relevant drugs.

MARKET INSIGHTS

Alzheimer's is a degenerative disorder that attacks the neurons, affecting thinking, memory loss, behavioral changes, and language skills. The market is anticipated to grow, driven by the vast number of last-stage pipeline and disease-modifying drugs. The United States is the largest player in Alzheimer's disease diagnostics and therapeutics market. Besides, the country also has high expenditure on disease management and high detection rates in primary care settings. According to the US Census Bureau, the population of Americans aged 65+ is expected to surge to 88 million by 2050. These factors are expected to drive the market growth during the forecast years.

Furthermore, the United States Food and Drug Administration has approved various molecules to treat Alzheimer's disease. Also, a combination drug containing Memantine and Donepezil is widely available in the market. The availability of various drugs and molecules to cure the disease produces lucrative opportunities for medicine manufacturers.

COMPETITIVE INSIGHTS

Leading players in the market include: GE Healthcare, Baxter International Inc, Amarantus Bioscience Holdings Inc, Cognoptix Inc, Merck & Co Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Product Code: 46192

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. COUNTRY SNAPSHOT
  • 2.3. COUNTRY ANALYSIS
  • 2.4. KEY GROWTH ENABLERS
  • 2.5. KEY CHALLENGES

3. KEY ANALYTICS

  • 3.1. PARENT MARKET ANALYSIS
  • 3.2. TIMELINE OF ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 3.3. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 3.4. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
  • 3.5. KEY MARKET TRENDS
  • 3.6. PORTER'S FIVE FORCES ANALYSIS
    • 3.6.1. BUYERS POWER
    • 3.6.2. SUPPLIERS POWER
    • 3.6.3. SUBSTITUTION
    • 3.6.4. NEW ENTRANTS
    • 3.6.5. INDUSTRY RIVALRY
  • 3.7. KEY BUYING CRITERIA
  • 3.8. SUPPLY CHAIN ANALYSIS
  • 3.9. OPPORTUNITY MATRIX
  • 3.10. PESTLE ANALYSIS - UNITED STATES

4. MARKET BY THERAPEUTICS & DIAGNOSTICS

  • 4.1. THERAPEUTICS
    • 4.1.1. DRUGS
      • 4.1.1.1. MARKETED DRUGS
      • 4.1.1.2. PIPELINE DRUGS
    • 4.1.2. DISEASE STAGE
      • 4.1.2.1. LATE-STAGE: SEVERE AD
      • 4.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 4.1.2.3. PRODROMAL STAGE
    • 4.1.3. GENERIC & BRANDED
      • 4.1.3.1. BRANDED
      • 4.1.3.2. GENERIC
  • 4.2. DIAGNOSTICS
    • 4.2.1. LUMBAR PUNCTURE TEST
    • 4.2.2. POSITRON EMISSION TOMOGRAPHY
    • 4.2.3. ELECTROENCEPHALOGRAPHY
    • 4.2.4. MAGNETIC RESONANCE IMAGING
    • 4.2.5. COMPUTED TOMOGRAPHY
    • 4.2.6. BLOOD TEST
    • 4.2.7. OTHER DIAGNOSTICS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIC DEVELOPMENTS
    • 5.1.1. MERGERS & ACQUISITIONS
    • 5.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 5.1.3. PARTNERSHIPS & AGREEMENTS
    • 5.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
  • 5.2. COMPANY PROFILES
    • 5.2.1. AMARANTUS BIOSCIENCE HOLDINGS INC
    • 5.2.2. BAXTER INTERNATIONAL INC
    • 5.2.3. BIOGEN INC
    • 5.2.4. COGNOPTIX INC
    • 5.2.5. ELI LILLY & COMPANY
    • 5.2.6. GE HEALTHCARE
    • 5.2.7. JOHNSON & JOHNSON
    • 5.2.8. MERCK & CO INC
    • 5.2.9. PFIZER INC

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS
  • TABLE 2: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 3: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2028 (IN $ MILLION)
  • TABLE 4: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 5: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2028 (IN $ MILLION)
  • TABLE 6: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 7: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2028 (IN $ MILLION)
  • TABLE 8: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 9: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2028 (IN $ MILLION)
  • TABLE 10: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 11: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2028 (IN $ MILLION)
  • TABLE 12: LIST OF MERGERS & ACQUISITIONS
  • TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 15: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: KEY MARKET TRENDS
  • FIGURE 3: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 4: KEY BUYING CRITERIA
  • FIGURE 5: SUPPLY CHAIN ANALYSIS
  • FIGURE 6: OPPORTUNITY MATRIX
  • FIGURE 7: PESTLE ANALYSIS - UNITED STATES
  • FIGURE 8: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
  • FIGURE 9: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2028 (IN $ MILLION)
  • FIGURE 10: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
  • FIGURE 11: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $ MILLION)
  • FIGURE 12: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $ MILLION)
  • FIGURE 13: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
  • FIGURE 14: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2028 (IN $ MILLION)
  • FIGURE 15: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2028 (IN $ MILLION)
  • FIGURE 16: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $ MILLION)
  • FIGURE 17: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
  • FIGURE 18: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)
  • FIGURE 19: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
  • FIGURE 20: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2028 (IN $ MILLION)
  • FIGURE 21: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
  • FIGURE 22: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN $ MILLION)
  • FIGURE 23: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2028 (IN $ MILLION)
  • FIGURE 24: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028 (IN $ MILLION)
  • FIGURE 25: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2028 (IN $ MILLION)
  • FIGURE 26: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $ MILLION)
  • FIGURE 27: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)
  • FIGURE 28: UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $ MILLION)